Member Login
  1. Stocks
    2. /
  2. Zymeworks Inc. (NYSE: ZYME)
    3. /

NYSE:ZYME (Zymeworks Inc.)

About ZYME

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Financial Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Zymeworks Inc. (NYSE: ZYME) Latest News

    Investing

    Swing for the Fences and Buy This Growth Stock in April

    | Ambrose O'Callaghan

    Zymeworks (TSX:ZYME)(NYSE:ZYME) is set to spend more on its promising product candidates in 2019 and 2020. This is a stock…

    Read more »

    Investing

    2 Biopharma Stocks to Add to Your TFSA Today

    | Ambrose O'Callaghan

    Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) and HLS Therapeutics Inc. (TSX:HLS) offer the potential for huge growth over the next decade.

    Read more »

    Investing

    Stash This Growth Stock in Your TFSA Forever

    | Ambrose O'Callaghan

    Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) stock holds huge promise going forward on the back of its flagship products ZW25 and ZW49.

    Read more »

    Investing

    TFSA Investors: 2 Stocks That Can Provide Massive Growth Over the Next Decade

    | Ambrose O'Callaghan

    Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) and Jamieson Wellness Inc. (TSX:JWEL) are promising companies in two markets that are poised for huge growth…

    Read more »

    growing dividends
    Investing

    2 Growth Stocks for Young Investors to Hold Forever

    | Ambrose O'Callaghan

    Jamieson Wellness Inc. (TSX:JWEL) and Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) are both huge growth opportunities that young investors should be targeting.

    Read more »

    Investing

    These Growth Stocks Could Surge With a New NAFTA Deal

    | Kenrick Vassall

    Pharmaceutical companies such as Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) could benefit from a new NAFTA deal that includes longer data protection for…

    Read more »

    Investing

    Sick of Cannabis Stocks? These 3 Biotech Stocks Offer Huge Growth Potential

    | Ambrose O'Callaghan

    Biotech stocks like Zymeworks (TSX:ZYME)(NYSE:ZYME) and others offer explosive long-term growth potential.

    Read more »

    Investing

    Young Investors: 3 Biotech Stocks That Can Electrify Your TFSA

    | Ambrose O'Callaghan

    Biotech stocks like Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) have soared in 2018 and have the potential to go much higher if flagship…

    Read more »

    Investing

    3 Stocks at 52-Week Highs: Should You Take Profits or Keep Stacking?

    | Ambrose O'Callaghan

    Trade anxiety could rattle markets, but that does not mean investors should run from stocks like Bombardier Inc. (TSX:BBD.B) and…

    Read more »

    Investing

    My Top 5 Growth Stocks to Add to Your TFSA Today

    | Ambrose O'Callaghan

    Stocks like Shopify Inc. (TSX:SHOP)(NYSE:SHOP) and others are worth a look for investors seeking big growth today.

    Read more »

    The Motley Fool
    Investing

    3 Growth Stocks in Rising Industries That Can Electrify Your TFSA for the Long Haul

    | Ambrose O'Callaghan

    Investors should target companies in rising industries, such as Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) and others.

    Read more »

    The Motley Fool
    Tech Stocks

    This Biotech Stock Has Surged Over 100% in 2018: Is it Still a Buy Today?

    | Ambrose O'Callaghan

    Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) stock has soared in 2018, as the company has generated excitement in early trials for its lead…

    Read more »